Today

Expensify launched a modified Dutch-auction to repurchase up to USD 25,000,000 of Class A stock at $0.98–$1.20 per share.

Fund offers to buy up to 10% of shares at 98% of NAV.

Amendment reports regulatory clearances and discloses shareholder lawsuits challenging the $27.00 tender offer.

GSK will tender its 74% stake in CureVac and support BioNTech's exchange offer.

Genmab acquired ~94.8% of Merus in a $97 cash tender offer; delisting planned.

Terra offers to exchange maturing 6.00% notes for 8.00% senior secured notes plus cash, extending maturity and raising financing risk.

Silver Lake affiliate SL SPV-2 sold 89,510 Dell shares for about $33.1M on June 3, 2026.

Saltchuk completed a $17.00-per-share cash tender; GLDD merged and is now a Saltchuk wholly owned subsidiary.

Saltchuk's subsidiary launched a $17 cash tender offer to acquire all outstanding GLDD shares.

CEO Sade Ron bought 1.149M shares for about $5.71M (~25% of float).

SoftBank-linked holder sold 5.59M shares for about $281.8M, leaving zero reported holdings.

Abercrombie & Fitch reported record Q1 net sales ($1.1B) and EPS of $1.47 that exceeded its outlook, maintained FY guidance and signaled sizable share repurchases — indicating continued operational momentum despite regional softness in EMEA.

BioLineRx reported Q1 2026 results and attached interim financials and an operating review that include a going-concern disclosure (accumulated losses of $403M). Company progress on GLIX1 (first patient dosed) is a positive development, but the going-concern and ongoing cash burn raise near-term financial risk.

TDAC announced a Business Combination Agreement to merge with ProLogium (dated May 27, 2026). The filing includes the merger agreement and related voting/lock‑up/registration exhibits, an implied equity value (~$3.8B), warrant terms ($11.50 exercise), and Available Cash and closing/deadline mechanics — a de‑SPAC transaction that will require shareholder approvals and affects listing, dilution and timing.

Algorhythm registered 10,000,000 resale shares while auditors cite substantial doubt about going concern.

Company registered 22.6M shares for resale; auditor issued going-concern opinion.

F-3 conversion registers large resale and warrant share overhang that may pressure BDMD shares.

S-1/A corrects an omitted auditor consent and references a going-concern.

S-4 registers shares and exhibits for proposed Allegro merger, PIPE and executive agreements.

Positive Phase 2 Part B readout: mid-dose zumilokibart showed substantially higher EASI-75 and IGA responses vs placebo at Week 16 with mid-dose selected as planned Phase 3 dose and acceptable conjunctivitis rates versus higher doses.